

10. Shortened treatment regimens for MDR-TB: results from the field and future direction

Thursday, 30 October 2014, 14:30 - 16:30

Room 112



Type Symposium

Track Tuberculosis

Topic Medical management of TB and drug resistant TB

Description Since early reports from Bangladesh of a promising, shorter and more tolerable and successful treatment regimen for MDR-TB, there has been great interest in the development and future direction of this revolutionary treatment approach. This session will provide an update of the original pilot population, as well as several additional pilot sites that have implemented the 'Bangladesh' regimen. The session will also highlight a global clinical trial on the shortened regimen, community involvement in regimen implementation and future direction of the regimen in light of new treatment options.

Target audience Programme managers, policy-makers, clinicians, academics, donors, technical organisations and community-based organisations involved in the delivery of MDR-TB care.

Objectives

1. To review the experiences/data to date on shortened MDR-TB regimens in multiple settings
2. To update the status and future direction of a global multi-country clinical trial evaluating the regimen
3. To review the role of the community in the implementation of the shortened regimen
4. To consider the future of the shortened regimen in light of new treatment options

Keywords MDR-TB; clinical research; community care; new drugs

Coordinator(s) I. D. Rusen (Canada), Tara Ornstein (USA)

Chair(s) Robert Horsburgh (USA), Chen-yuan Chiang (Taiwan)

Presentations

14:30 - 14:45 Shortened MDR-TB treatment in Bangladesh: a decade of results
Armand Van Deun (Belgium)

14:50 - 15:05 Expanding shortened MDR-TB treatment: the West African experience
Arnaud Trebucq (France)

15:10 - 15:25 STREAM: a multi-country clinical trial evaluating the shortened MDR-TB regimen
Andrew Nunn (UK)

15:30 - 15:45 Community involvement in shortened MDR-TB regimen implementation
Abdul Hamid (Bangladesh)

15:50 - 16:05 Future direction for shortened MDR-TB regimens with access to new medicines
Michael Rich (USA)

16:10 - 16:30 Discussion